search
Medical Daily
Trends
- 1Long-Acting Cabotegravir/Rilpivirine Shot Outperforms Daily Oral HIV Therapy●Long-Acting Cabotegravir/Rilpivirine Superior to Daily Oral ART for HIV
New findings indicate that long-acting injectable cabotegravir/rilpivirine, given every one to two months, is superior to daily oral antiretroviral therapy for suppressing HIV. The two-drug injectable regimen offers an alternative to pills, potentially improving adherence for patients who struggle with daily medication. Clinicians are weighing the results for future treatment guidelines.